CEO Executive AssistantExternal innovation pharma CEO engagement is one of the most time-demanding responsibilities in the role – and one of the most difficult to structure efficiently. Business development, licensing, partnerships, and acquisitions are how most pharma and biotech companies access the scientific innovation that fuels their pipelines. A BD-inactive CEO risks a pipeline that is dependent entirely on internal research. A BD-overactive CEO fragments their attention across dozens of opportunities that collectively consume weeks of calendar time without producing proportionate value.
The executives who manage external innovation well have a clear framework for what types of opportunities deserve CEO attention, a reliable process for evaluating and executing deals, and a BD organization with genuine capability to source and assess opportunities without constant CEO direction.
The CEO’s Unique Role in External Innovation
Business development transactions ultimately require CEO decision and, for significant deals, CEO relationship management with counterpart organizations. But the CEO’s role in BD is not to generate deal flow, not to conduct due diligence, and not to manage the transaction process. Those belong to your BD team.
The CEO’s unique contributions to external innovation:
Defining the innovation thesis: What gaps in your pipeline does external innovation need to fill? What scientific capabilities or technologies are you seeking that internal research cannot build as efficiently as licensing or acquisition? This strategic framing shapes which opportunities are worth evaluating and which are outside scope.
Counterpart relationship management: For major transactions – platform acquisitions, significant partnership agreements, co-development deals with major companies – the CEO’s direct engagement with the counterpart’s CEO or senior leadership is often essential for deal execution. Deals that stall at the business development team level frequently move when CEO-to-CEO conversation opens the possibility.
Go/no-go on major transactions: The final decision on acquisitions, major licensing deals, and significant platform partnerships requires CEO ownership and board approval for transactions above defined thresholds.
External innovation culture: Signaling to the organization that external innovation is genuinely valued – not viewed as an admission that internal research is inadequate – requires CEO communication and behavior that reinforces the BD function’s strategic importance.
Structuring Your External Innovation Time
Define the Innovation Thesis Annually
Before the start of each calendar year, your BD leadership and Chief Scientific Officer should present an innovation thesis: the specific scientific areas, modalities, mechanisms, and stage profiles that represent the highest-priority external innovation targets for the coming year.
This thesis should be informed by your pipeline gap analysis (what does your pipeline need that it does not have), your scientific strategy (what platforms or capabilities would accelerate your development programs), and your commercial strategy (what products or technologies would strengthen your competitive position in priority therapeutic areas).
The CEO’s role in developing this thesis is to ensure strategic alignment between BD priorities and the company’s overall direction – not to generate the thesis independently. Once aligned, this thesis guides your BD team’s sourcing activities and gives them a clear mandate for what opportunities are worth bringing to you.
CEO Direct Engagement: When and With Whom
Not every potential deal warrants CEO engagement. Your BD team manages the outreach, evaluation, and early negotiation for the large majority of opportunities that come through your pipeline. The CEO enters when:
- The opportunity is large enough to require board approval or materially affect the company’s strategy
- The transaction requires CEO-to-CEO relationship investment to advance or close
- The scientific or strategic implications of the deal require CEO judgment that the BD team cannot provide
- The counterpart company is seeking CEO reassurance about your company’s commitment before proceeding
For transactions that meet these criteria, your BD team prepares you with a focused brief: the opportunity summary, what you are trying to accomplish in the meeting or call, and the specific questions or decisions at stake. A 30-minute preparation session before any CEO BD engagement is a standard and worthwhile investment.
Conference and Relationship-Based Innovation Sourcing
Major scientific and industry conferences are significant external innovation sourcing venues. At JPM Healthcare Conference, BIO, ASCO, AACR, and equivalent meetings, biotech CEOs present programs that may be partnership or acquisition candidates. Your BD team attends these conferences systematically. The CEO’s attendance creates opportunities for relationship development with company leadership that BD teams cannot build alone.
Structure your conference attendance to include one to two BD-specific meetings per day at major conferences – not investor meetings, but meetings with CEOs of companies that are in the range of your external innovation thesis. These conversations are relationship investments, not deal negotiations. They build the network of personal connections that often generates deal opportunities before they reach formal BD processes.
Your BD team should prepare a target list for each major conference: which companies are worth CEO engagement and why. You can assess five to ten potential partnerships or acquisition targets over the course of a two-day conference through focused 30 to 45-minute conversations.
Transaction Evaluation: CEO Role in Due Diligence
For major transactions, the CEO participates in select due diligence activities, not in the full due diligence program. Specifically:
Management team evaluation: For company acquisitions, the CEO should directly assess the leadership team of the target company through structured interviews or focused meetings. The quality of the team you are acquiring is a material determinant of transaction success.
Scientific thesis validation: For scientific platform acquisitions, the CEO should be briefed on the due diligence findings by your CSO and external scientific advisors, with sufficient depth to make a confident assessment of the scientific foundation of the transaction.
Strategic fit assessment: The CEO should review the final due diligence findings with explicit attention to how this transaction advances the company’s strategy – not just whether the deal terms are favorable in isolation.
The pipeline review cadence is the natural forum for reviewing the strategic fit of BD opportunities against your current pipeline. Proposed acquisitions or licensing deals should be assessed against your existing portfolio: do they fill gaps, create redundancy, or shift your portfolio’s therapeutic focus in a way that requires board alignment?
Managing the BD Organization
Your BD organization needs a clear mandate, adequate resources, and CEO backing to build the external relationships that generate deal flow. Under-resourced BD organizations are reactive (waiting for inbound opportunities) rather than proactive (systematically cultivating the external innovation network). Reactive BD organizations see only the opportunities that others are already actively shopping – not the early, proprietary opportunities that produce the best deal terms.
Your Head of BD or Chief Business Officer should have direct CEO access and should meet with you on a defined cadence: weekly for 15 minutes during active deal processes, bi-weekly for 30 minutes during standard pipeline management periods. The CEO should not be the bottleneck in BD processes – deals that require multiple rounds of escalation to get CEO attention develop reputational damage in the external community over time.
External Innovation and Partner Relationship Management
Licensing deals and co-development partnerships are not single transactions. They are ongoing relationships that require executive-level maintenance to produce the value they were structured to deliver.
For Tier 1 partnerships – co-development programs with material clinical and commercial implications – build CEO touchpoints into the relationship cadence: a quarterly or semi-annual strategic review with your counterpart’s senior leadership, direct communication when major milestones are achieved or when partnership issues require executive escalation.
Your BD team manages the day-to-day partnership governance. The CEO’s engagement is reserved for the relationship maintenance that keeps major partnerships productive and the escalation resolution that unblocks partnership issues that operational teams cannot resolve.
The board reporting pharma function should include a summary of major partnership status as a standing board agenda item, ensuring directors have visibility into the partnerships that represent significant strategic and financial commitments.
Conclusion
External innovation pharma CEO management is a discipline of selective, intentional engagement. Your external innovation thesis defines the opportunities worth pursuing. Your BD organization identifies and evaluates those opportunities. Your CEO engagement concentrates on counterpart relationships for major deals, final go/no-go decisions, and strategic alignment of transactions with portfolio direction. The CEOs who build this architecture effectively – and who invest the conference time and relationship cultivation that generates proprietary deal flow – build pipelines that consistently outperform those dependent solely on internal research or reactive BD processes.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.